Yuan Yuan1, Jin Sun Lee2, Susan E Yost2, Paul H Frankel3, Christopher Ruel3, Colt A Egelston4, Weihua Guo4, Simran Padam2, Aileen Tang2, Norma Martinez2, Daniel Schmolze5, Cary Presant2, Behnam Ebrahimi2, Christina Yeon2, Mina Sedrak2, Niki Patel2, Jana Portnow2, Peter Lee4, Joanne Mortimer2. 1. Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA. Electronic address: yuyuan@coh.org. 2. Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA. 3. Department of Biostatistics, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA. 4. Department of Immune-Oncology, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA. 5. Department of Pathology, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
Abstract
BACKGROUND: CDK4/6 inhibitors modulate immune response in breast cancer. This phase I/II trial was designed to test the safety and efficacy of palbociclib, pembrolizumab and letrozole in women with hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with stage IV HR+ HER2- MBC were enrolled and treated with palbociclib, pembrolizumab and letrozole. Primary end-points were safety, tolerability and efficacy. RESULTS: Between November 2016 and July 2020, 23 patients were enrolled with 20 evaluable for response, including 4 patients in cohort 1 and 16 patients in cohort 2. Cohort 1 median age was 48 years (33-70) and cohort 2 median age was 55 (37-75). Cohort 1 closed early due to limited accrual. Grade III-IV adverse events were neutropenia (83%), leucopaenia (65%), thrombocytopenia (17%) and elevated liver enzymes (17%). In cohort 1, 50% achieved a partial response (PR) and 50% had stable disease (SD). In cohort 2, 31% achieved complete response (CR), 25% had PR and 31% had SD by Response Evaluation Criteria in Solid Tumours version 1.1. Median progression-free survival was 25.2 months (95% confidence interval [CI] 5.3, not reached) and median overall survival was 36.9 months (95% CI 36.9, not reached) in cohort 2 with a median follow-up of 24.8 months (95% CI 17.1, not reached). A correlative immune biomarker analysis was published separately. CONCLUSION: The combination of palbociclib, pembrolizumab and letrozole is well tolerated, and a complete response rate of 31% was identified in HR+ MBC patients who received this combination as front-line therapy. Confirmatory trials are required to better understand the immune-priming effects of CDK4/6 inhibitors.
BACKGROUND: CDK4/6 inhibitors modulate immune response in breast cancer. This phase I/II trial was designed to test the safety and efficacy of palbociclib, pembrolizumab and letrozole in women with hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with stage IV HR+ HER2- MBC were enrolled and treated with palbociclib, pembrolizumab and letrozole. Primary end-points were safety, tolerability and efficacy. RESULTS: Between November 2016 and July 2020, 23 patients were enrolled with 20 evaluable for response, including 4 patients in cohort 1 and 16 patients in cohort 2. Cohort 1 median age was 48 years (33-70) and cohort 2 median age was 55 (37-75). Cohort 1 closed early due to limited accrual. Grade III-IV adverse events were neutropenia (83%), leucopaenia (65%), thrombocytopenia (17%) and elevated liver enzymes (17%). In cohort 1, 50% achieved a partial response (PR) and 50% had stable disease (SD). In cohort 2, 31% achieved complete response (CR), 25% had PR and 31% had SD by Response Evaluation Criteria in Solid Tumours version 1.1. Median progression-free survival was 25.2 months (95% confidence interval [CI] 5.3, not reached) and median overall survival was 36.9 months (95% CI 36.9, not reached) in cohort 2 with a median follow-up of 24.8 months (95% CI 17.1, not reached). A correlative immune biomarker analysis was published separately. CONCLUSION: The combination of palbociclib, pembrolizumab and letrozole is well tolerated, and a complete response rate of 31% was identified in HR+ MBC patients who received this combination as front-line therapy. Confirmatory trials are required to better understand the immune-priming effects of CDK4/6 inhibitors.
Authors: R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: R Condorelli; L Spring; J O'Shaughnessy; L Lacroix; C Bailleux; V Scott; J Dubois; R J Nagy; R B Lanman; A J Iafrate; F Andre; A Bardia Journal: Ann Oncol Date: 2018-03-01 Impact factor: 32.976
Authors: Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: N Engl J Med Date: 2018-10-20 Impact factor: 91.245
Authors: Todd W Miller; Justin M Balko; Emily M Fox; Zara Ghazoui; Anita Dunbier; Helen Anderson; Mitch Dowsett; Aixiang Jiang; R Adam Smith; Sauveur-Michel Maira; H Charles Manning; Ana M González-Angulo; Gordon B Mills; Catherine Higham; Siprachanh Chanthaphaychith; Maria G Kuba; William R Miller; Yu Shyr; Carlos L Arteaga Journal: Cancer Discov Date: 2011-07-20 Impact factor: 39.397
Authors: Seth A Wander; Ofir Cohen; Xueqian Gong; Gabriela N Johnson; Jorge E Buendia-Buendia; Maxwell R Lloyd; Dewey Kim; Flora Luo; Pingping Mao; Karla Helvie; Kailey J Kowalski; Utthara Nayar; Adrienne G Waks; Stephen H Parsons; Ricardo Martinez; Lacey M Litchfield; Xiang S Ye; Chunping Yu; Valerie M Jansen; John R Stille; Patricia S Smith; Gerard J Oakley; Quincy S Chu; Gerald Batist; Melissa E Hughes; Jill D Kremer; Levi A Garraway; Eric P Winer; Sara M Tolaney; Nancy U Lin; Sean G Buchanan; Nikhil Wagle Journal: Cancer Discov Date: 2020-05-13 Impact factor: 39.397
Authors: Nicolas A Giraldo; Rafael Sanchez-Salas; J David Peske; Yann Vano; Etienne Becht; Florent Petitprez; Pierre Validire; Alexandre Ingels; Xavier Cathelineau; Wolf Herman Fridman; Catherine Sautès-Fridman Journal: Br J Cancer Date: 2018-11-09 Impact factor: 7.640
Authors: Anne Y Lai; Jessica A Sorrentino; Konstantin H Dragnev; Jared M Weiss; Taofeek K Owonikoko; Julie A Rytlewski; Jill Hood; Zhao Yang; Rajesh K Malik; Jay C Strum; Patrick J Roberts Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751
Authors: Zuzana Tatarova; Dylan C Blumberg; James E Korkola; Laura M Heiser; John L Muschler; Pepper J Schedin; Sebastian W Ahn; Gordon B Mills; Lisa M Coussens; Oliver Jonas; Joe W Gray Journal: Nat Biotechnol Date: 2022-07-04 Impact factor: 68.164
Authors: Xuan Ge; Susan E Yost; Jin Sun Lee; Paul H Frankel; Christopher Ruel; Yujie Cui; Mireya Murga; Aileen Tang; Norma Martinez; Samuel Chung; Christina Yeon; Daphne Stewart; Daneng Li; Swapnil Rajurkar; George Somlo; Joanne Mortimer; James Waisman; Yuan Yuan Journal: Cancers (Basel) Date: 2022-09-01 Impact factor: 6.575